Branch retinal vein occlusion: classification and treatment.
Branch retinal vein occlusion (BRVO) refers to a heterogeneous group of disorders with different clinical aspects, courses, and probably therapy. Depending on the site of the arteriovenous crossing, we can roughly divide BRVO into 3 main groups: major BRVO, hemispheric retinal vein occlusion, and macular BRVO. Main treatment options include laser treatment, corticosteroid administration, anti-VEGF drugs, and sheathotomy with or without vitrectomy. Laser photocoagulation, as demonstrated by the Branch Vein Occlusion Study, represents the gold standard for the treatment of macular edema and ocular neovascularization following BRVO. The limited functional outcomes achievable by means of laser treatment have prompted researchers to try alternative options, with varying results. The recent introduction of combined therapies for macular edema may provide a superior approach in an attempt to improve and stabilize visual acuity over a long-term follow-up.
Parodi
Maurizio Battaglia
MB
Department of Ophthalmology, University of Udine, Udine, Italy.
Bandello
Francesco
F
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D017075:Laser Coagulation; D013508:Ophthalmologic Surgical Procedures; D012170:Retinal Vein Occlusion / Q000145:classification* / Q000628:therapy*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D005938:Glucocorticoids; D042461:Vascular Endothelial Growth Factor A